MESENCHYMAL STEM CELL THERAPY FOR INFARCT PROJ 3 2009

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 近三分之二的糖尿病患者患有明显的心血管疾病，包括冠状动脉疾病，心肌梗死（MI）和心肌病。尽管已知糖尿病的全身性质，但MI和缺血性心肌病的治疗通常不专门针对糖尿病患者，并且干细胞治疗用于糖尿病患者梗死修复的可行性和有效性仍不清楚。虽然间充质干细胞（MSC）已被证明可以诱导梗死修复，但结果是可变的，机制仍然存在争议。MSC介导的心脏修复的变异性可能源于普通“MSC”的根本异质性。我们假设使用具有更大内皮和心肌分化潜力以及更大分泌心脏保护因子能力的同质抗原定义的MSC亚群将导致糖尿病患者的上级心脏修复。这些研究将确定用于糖尿病患者梗死修复的最佳MSC，结果将对患有缺血性心脏病和MI后心力衰竭的糖尿病患者产生巨大的治疗意义。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nearly two-thirds of diabetics suffer from overt cardiovascular conditions, including coronary artery disease, myocardial infarction (MI), and cardiomyopathy. Despite the known systemic nature of diabetes, therapy for MI and ischemic cardiomyopathy are often not specifically tailored for diabetics, and the feasibility and efficacy of stem cell therapy for infarct repair in diabetic patients remains unclear. Although mesenchymal stem cells (MSCs) have been shown to induce infarct repair, the results have been variable and mechanisms remain controversial. The variability in MSC-mediated cardiac repair might have stemmed from the fundamentally heterogeneous nature of unfractionated 'MSCs'. We hypothesize that the use of a homogenous antigenically-defined MSC subpopulation with greater endothelial and cardiomyogenic differentiation potential and greater ability to secrete cardioprotective factors will result in superior cardiac repair in diabetics. These studies will identify the best MSC to use for infarct repair specifically in diabetics, and the results would have enormous therapeutic implications for diabetic patients with ischemic heart disease and post-MI heart failure.